File Download
Supplementary
-
Citations:
- Appears in Collections:
Article: Telbivudine: a new treatment option in the management of chronic hepatitis B
Title | Telbivudine: a new treatment option in the management of chronic hepatitis B |
---|---|
Authors | |
Keywords | Medical sciences Communicable diseases |
Issue Date | 2006 |
Publisher | Medknow Publications Pvt Ltd. The Journal's web site is located at http://www.hepatitisbannual.org |
Citation | Hepatitis B Annual, 2006, v. 3 n. 1, p. 14-34 How to Cite? |
Abstract | Chronic hepatitis B virus (HBV) infection affects over 350 million individuals worldwide. Chronic hepatitis B is associated with complications of end-stage liver disease, including cirrhosis and hepatocellular carcinoma. Six drugs have been approved for the treatment of chronic hepatitis B: interferon-alpha, pegylated interferon-alpha, lamivudine, adefovir dipivoxil, entecavir and recently telbivudine. Most agents designed to target hepatitis B are hindered by the development of resistance, poor tolerability or limited efficacy; therefore, the search for new agents and treatment strategies continues. Telbivudine is the latest approved anti-HBV agent; it is an orally administered nucleoside analog that selectively inhibits HBV replication. It has demonstrated potent activity against HBV in clinical studies, with good tolerance, lack of mitochondrial toxicity and no dose-limiting side effects. This review focuses on telbivudine, the latest oral antiviral agent for the treatment of chronic hepatitis B. |
Persistent Identifier | http://hdl.handle.net/10722/57528 |
ISSN |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fung, J | en_HK |
dc.contributor.author | Lai, CL | en_HK |
dc.contributor.author | Yuen, MF | en_HK |
dc.date.accessioned | 2010-04-12T01:39:11Z | - |
dc.date.available | 2010-04-12T01:39:11Z | - |
dc.date.issued | 2006 | en_HK |
dc.identifier.citation | Hepatitis B Annual, 2006, v. 3 n. 1, p. 14-34 | en_HK |
dc.identifier.issn | 0972-9747 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/57528 | - |
dc.description.abstract | Chronic hepatitis B virus (HBV) infection affects over 350 million individuals worldwide. Chronic hepatitis B is associated with complications of end-stage liver disease, including cirrhosis and hepatocellular carcinoma. Six drugs have been approved for the treatment of chronic hepatitis B: interferon-alpha, pegylated interferon-alpha, lamivudine, adefovir dipivoxil, entecavir and recently telbivudine. Most agents designed to target hepatitis B are hindered by the development of resistance, poor tolerability or limited efficacy; therefore, the search for new agents and treatment strategies continues. Telbivudine is the latest approved anti-HBV agent; it is an orally administered nucleoside analog that selectively inhibits HBV replication. It has demonstrated potent activity against HBV in clinical studies, with good tolerance, lack of mitochondrial toxicity and no dose-limiting side effects. This review focuses on telbivudine, the latest oral antiviral agent for the treatment of chronic hepatitis B. | en_HK |
dc.language | eng | en_HK |
dc.publisher | Medknow Publications Pvt Ltd. The Journal's web site is located at http://www.hepatitisbannual.org | en_HK |
dc.rights | Hepatitis B Annual. Copyright © Medknow Publications Pvt Ltd. | en_HK |
dc.subject | Medical sciences | en_HK |
dc.subject | Communicable diseases | en_HK |
dc.title | Telbivudine: a new treatment option in the management of chronic hepatitis B | en_HK |
dc.type | Article | en_HK |
dc.identifier.openurl | http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0972-9747&volume=3&issue=1&spage=14&epage=34&date=2006&atitle=Telbivudine:+a+new+treatment+option+in+the+management+of+chronic+hepatitis+B | en_HK |
dc.identifier.email | Fung, J: jfung@sicklehut.com | en_HK |
dc.identifier.email | Lai, CL: hrmelcl@hku.hk | en_HK |
dc.identifier.email | Yuen, MF: mfyuen@hkucc.hku.hk | en_HK |
dc.description.nature | published_or_final_version | en_HK |
dc.identifier.hkuros | 132174 | - |
dc.identifier.issnl | 0972-9747 | - |